Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression

被引:8
作者
Ikezawa, Yasuyuki [1 ]
Mizugaki, Hidenori [2 ,3 ]
Morita, Ryo [4 ]
Tateishi, Kazunari [5 ]
Yokoo, Keiki [6 ]
Sumi, Toshiyuki [7 ]
Kikuchi, Hajime [8 ]
Kitamura, Yasuo [9 ]
Nakamura, Atsushi [10 ]
Kobayashi, Maki [11 ]
Aso, Mari [12 ]
Kimura, Nozomu [13 ]
Yoshiike, Fumiaki [14 ]
Furuta, Megumi [3 ]
Tanaka, Hisashi [15 ]
Sekikawa, Motoki [16 ]
Hachiya, Tsutomu [17 ]
Nakamura, Keiichi [18 ]
Shimokawa, Mototsugu [19 ]
Oizumi, Satoshi [20 ]
机构
[1] Oji Gen Hosp, Dept Resp Med, Tomakomai, Japan
[2] Japanese Fdn Canc Res, Dept Adv Med Dev, Canc Inst Hosp, Tokyo, Japan
[3] Hokkaido Univ, Fac Med, Dept Resp Med, Sapporo, Hokkaido, Japan
[4] Akita Kousei Med Ctr, Dept Resp Med, Akita, Japan
[5] Shinshu Univ, Dept Internal Med 1, Sch Med, Matsumoto, Nagano, Japan
[6] Teine Keijinkai Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[7] Hakodate Goryoukaku Hosp, Dept Resp Med, Hakodate, Hokkaido, Japan
[8] Obihiro Kousei Gen Hosp, Dept Resp Med, Obihiro, Hokkaido, Japan
[9] Kushiro City Gen Hosp, Dept Resp Med, Kushiro, Japan
[10] Sendai Kousei Gen Hosp, Dept Resp Med, Sendai, Miyagi, Japan
[11] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[12] Yamagata Prefectural Cent Hosp, Dept Resp Med, Yamagata, Japan
[13] Tohoku Univ, Dept Resp Med, Grad Sch Med, Sendai, Miyagi, Japan
[14] Nagano Municipal Hosp, Dept Resp Med, Nagano, Japan
[15] Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Aomori, Japan
[16] Steel Mem Muroran Hosp, Dept Resp Med, Muroran, Hokkaido, Japan
[17] Japanese Red Cross Soc Suwa Hosp, Dept Resp Med, Suwa, Japan
[18] Natl Hosp Org, Dept Resp Med, Asahikawa Med Ctr, Asahikawa, Hokkaido, Japan
[19] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Yamaguchi, Japan
[20] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Sapporo, Hokkaido, Japan
关键词
combination chemotherapy; non-small-cell lung cancer; PD-L1; inhibitor; pembrolizumab; retrospective study; CHEMOTHERAPY; CRITERIA;
D O I
10.1111/cas.15361
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected for patients with advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (tumor proportion score >= 50%). We performed a retrospective, multicenter study of 300 patients with NSCLC exhibiting high PD-L1 expression who received MONO or COMB as first-line treatment between December 2018 and January 2020. We reviewed the medical records of all consecutive patients with no driver mutations, and assessed the patient characteristics, therapeutic regimens, treatment periods, and adverse events. In total, 166 (55%; median age: 74 years) and 134 (45%; median age: 68 years) patients received MONO and COMB, respectively. Patients were younger and had better performance status (0-1) in the COMB group (p < 0.01). With a median follow-up time of 10.6 (range: 0.1-20.6) months, the median progression-free survival was 7.1 months with MONO and 13.1 months with COMB. The objective response rate was 42.2% with MONO and 67.9% with COMB. With respect to treatment discontinuation, 36 out of 166 (21.7%) and 28 out of 134 (20.1%) patients discontinued MONO and COMB, respectively. In conclusion, COMB may be a promising option for first-line treatment for NSCLC with high PD-L1 expression and good performance status.
引用
收藏
页码:2109 / 2117
页数:9
相关论文
共 13 条
[1]   Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].
Aguilar, E. J. ;
Ricciuti, B. ;
Gainor, J. F. ;
Kehl, K. L. ;
Kravets, S. ;
Dahlberg, S. ;
Nishino, M. ;
Sholl, L. M. ;
Adeni, A. ;
Subegdjo, S. ;
Khosrowjerdi, S. ;
Peterson, R. M. ;
Digumarthy, S. ;
Liu, C. ;
Sauter, J. ;
Rizvi, H. ;
Arbour, K. C. ;
Carter, B. W. ;
Heymach, J. V. ;
Altan, M. ;
Hellmann, M. D. ;
Awad, M. M. .
ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659
[2]   First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study [J].
Amrane, Karim ;
Geier, Margaux ;
Corre, Romain ;
Lena, Herve ;
Leveiller, Guillaume ;
Gadby, Florence ;
Lamy, Regine ;
Bizec, Jean-Louis ;
Goarant, Eric ;
Robinet, Gilles ;
Gouva, Sylvie ;
Quere, Gilles ;
Abgral, Ronan ;
Schick, Ulrike ;
Bernier, Cyril ;
Chouaid, Christos ;
Descourt, Renaud .
CANCER MEDICINE, 2020, 9 (07) :2309-2316
[3]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[4]   Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies [J].
Freites-Martinez, A. ;
Santana, N. ;
Arias-Santiago, S. ;
Viera, A. .
ACTAS DERMO-SIFILIOGRAFICAS, 2021, 112 (01) :90-92
[5]   Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer [J].
Gadgeel, Shirish ;
Rodriguez-Abreu, Delvys ;
Speranza, Giovanna ;
Esteban, Emilio ;
Felip, Enriqueta ;
Domine, Manuel ;
Hui, Rina ;
Hochmair, Maximilian J. ;
Clingan, Philip ;
Powell, Steven F. ;
Cheng, Susanna Yee-Shan ;
Bischoff, Helge G. ;
Peled, Nir ;
Grossi, Francesco ;
Jennens, Ross R. ;
Reck, Martin ;
Garon, Edward B. ;
Novello, Silvia ;
Rubio-Viqueira, Belen ;
Boyer, Michael ;
Kurata, Takayasu ;
Gray, Jhanelle E. ;
Yang, Jing ;
Bas, Tuba ;
Pietanza, M. Catherine ;
Garassino, Marina C. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) :1505-+
[6]   Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].
Kanda, Y. .
BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458
[7]   Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis [J].
Liu, Jie ;
Li, Chengming ;
Seery, Samuel ;
Yu, Jinming ;
Meng, Xue .
ONCOIMMUNOLOGY, 2020, 9 (01)
[8]   Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J].
Mok, Tony S. K. ;
Wu, Yi-Long ;
Kudaba, Iveta ;
Kowalski, Dariusz M. ;
Cho, Byoung Chul ;
Turna, Hande Z. ;
Castro, Gilberto, Jr. ;
Srimuninnimit, Vichien ;
Laktionov, Konstantin K. ;
Bondarenko, Igor ;
Kubota, Kaoru ;
Lubiniecki, Gregory M. ;
Zhang, Jin ;
Kush, Debra ;
Lopes, Gilberto .
LANCET, 2019, 393 (10183) :1819-1830
[9]   A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 [J].
Paz-Ares, Luis ;
Vicente, David ;
Tafreshi, Ali ;
Robinson, Andrew ;
Parra, Hector Soto ;
Mazieres, Julien ;
Hermes, Barbara ;
Cicin, Irfan ;
Medgyasszay, Balazs ;
Rodriguez-Cid, Jeronimo ;
Okamoto, Isamu ;
Lee, SungSook ;
Ramlau, Rodryg ;
Vladimirov, Vladimir ;
Cheng, Ying ;
Deng, Xuan ;
Zhang, Ying ;
Bas, Tuba ;
Piperdi, Bilal ;
Halmos, Balazs .
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) :1657-1669
[10]   A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies [J].
Qu, Jialin ;
Wang, Li ;
Jiang, Man ;
Zhao, Deze ;
Wang, Yuyang ;
Zhang, Feng ;
Li, Jing ;
Zhang, Xiaochun .
CANCER MANAGEMENT AND RESEARCH, 2020, 12 :6493-6509